What happens when your lead asset is in a head-to-head race with three larger companies for the same, limited pool of patients? For any Head of Clinical Operations, this is a nightmare scenario where every single day counts. This is the story of how one of our partners won that race.
The Scenario: An emerging biotech, had a promising therapy for a specific subset of non-small cell lung cancer (NSCLC) and an aggressive 12-month enrollment deadline from their board. Their initial site list was composed of well-known academic centers, but these sites were already running competing trials.
The Strategic Pivot: Instead of fighting a losing battle for oversaturated sites, we deployed the AcceleROUTE™ framework. Our WideSCOPE Intelligence™ platform analyzed global data to identify a hidden portfolio of high-potential sites across North America and Eastern Europe that had strong track records but no directly competing studies.
Proactive Performance Management: Once activated, site performance was tracked in real-time. Our system flagged two sites with higher-than-expected screen-fail rates due to a specific lab value in the exclusion criteria. Our medical monitor immediately engaged with the PIs, provided clarifying guidance, and resolved the issue within a week, preventing a slowdown that would have gone unnoticed for weeks in a traditional model.
The Quantifiable Outcome: The result of this data-driven, proactive approach was transformative. The biotech completed full enrollment in just 9 months, a 25% acceleration from their original timeline.
This case study proves that in a competitive environment, the right site strategy is your greatest advantage.
Download our new White Paper,
“From selection to success“, for the complete framework.